title: [How we indicate oral antidiabetics today (from metformin to gliptins and gliflozins)].
abstract: Today we treat Type 2 diabetes mellitus by gradually adding antidiabetics from monotherapy to double, triple and multi combinations of medicines. Metformin still remains the first-line medicine, if well tolerated and not contraindicated. In the next step, we have a wide choice of 5 groups of medicines at least. The new algorithms used in the U.S.A. introduce some degree of preference for the incretin therapy (gliptins and incretin analogues) and the new groups of gliflozins over the standard treatments. In the near future, the indication of antidiabetics is therefore about to undergo big changes or at least a discussion about the preferences of the individual groups of medicines including those new to diabetology.Key words: gliflozins - gliptins - incretin therapy - metformin - oral antidiabetics - type 2 diabetes mellitus.
authors.forename: Stěpán
authors.initials: S
authors.lastname: Svačina